GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » Cyclically Adjusted PS Ratio

Biomarin Pharmaceutical (FRA:BM8) Cyclically Adjusted PS Ratio : 4.83 (As of Jun. 02, 2025)


View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Cyclically Adjusted PS Ratio?

As of today (2025-06-02), Biomarin Pharmaceutical's current share price is €51.38. Biomarin Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €10.63. Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio for today is 4.83.

The historical rank and industry rank for Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:BM8' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.95   Med: 12.83   Max: 44.11
Current: 5.06

During the past years, Biomarin Pharmaceutical's highest Cyclically Adjusted PS Ratio was 44.11. The lowest was 4.95. And the median was 12.83.

FRA:BM8's Cyclically Adjusted PS Ratio is ranked better than
51.81% of 496 companies
in the Biotechnology industry
Industry Median: 5.54 vs FRA:BM8: 5.06

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biomarin Pharmaceutical's adjusted revenue per share data for the three months ended in Mar. 2025 was €3.508. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €10.63 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biomarin Pharmaceutical Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Cyclically Adjusted PS Ratio Chart

Biomarin Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.73 11.16 11.49 9.59 5.91

Biomarin Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.38 7.72 6.43 5.91 6.16

Competitive Comparison of Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio falls into.


;
;

Biomarin Pharmaceutical Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=51.38/10.63
=4.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomarin Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Biomarin Pharmaceutical's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=3.508/134.9266*134.9266
=3.508

Current CPI (Mar. 2025) = 134.9266.

Biomarin Pharmaceutical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 1.389 100.684 1.861
201509 1.155 100.392 1.552
201512 1.298 99.792 1.755
201603 1.316 100.470 1.767
201606 1.643 101.688 2.180
201609 1.487 101.861 1.970
201612 1.652 101.863 2.188
201703 1.644 102.862 2.156
201706 1.620 103.349 2.115
201709 1.601 104.136 2.074
201712 1.725 104.011 2.238
201803 1.719 105.290 2.203
201806 1.804 106.317 2.289
201809 1.891 106.507 2.396
201812 1.737 105.998 2.211
201903 1.989 107.251 2.502
201906 1.917 108.070 2.393
201909 2.252 108.329 2.805
201912 2.278 108.420 2.835
202003 2.428 108.902 3.008
202006 2.110 108.767 2.617
202009 2.048 109.815 2.516
202012 2.044 109.897 2.510
202103 2.214 111.754 2.673
202106 2.246 114.631 2.644
202109 1.896 115.734 2.210
202112 2.169 117.630 2.488
202203 2.420 121.301 2.692
202206 2.694 125.017 2.908
202209 2.750 125.227 2.963
202212 2.728 125.222 2.939
202303 2.866 127.348 3.037
202306 2.818 128.729 2.954
202309 2.849 129.860 2.960
202312 3.144 129.419 3.278
202403 2.996 131.776 3.068
202406 3.299 132.554 3.358
202409 3.408 133.029 3.457
202412 3.627 133.157 3.675
202503 3.508 134.927 3.508

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biomarin Pharmaceutical  (FRA:BM8) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Biomarin Pharmaceutical Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Biomarin Pharmaceutical Headlines

No Headlines